Comparative Pharmacology
Head-to-head clinical analysis: CHLOROMYXIN versus CYCLACILLIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CHLOROMYXIN versus CYCLACILLIN.
CHLOROMYXIN vs CYCLACILLIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Chloromyxin is a combination product of chloramphenicol and polymyxin B. Chloramphenicol inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, preventing peptide bond formation. Polymyxin B disrupts bacterial cell membrane integrity by interacting with lipopolysaccharides in gram-negative bacteria.
Cyclacillin is a beta-lactam antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell lysis and death.
500 mg IV every 6 hours or 1 g IV every 12 hours; infusion over 30 minutes.
250-500 mg orally every 6 hours.
None Documented
None Documented
CHLOROMYXIN is not a recognized drug. No data available.
Clinical Note
moderateCyclacillin + Probenecid
"The serum concentration of Probenecid can be increased when it is combined with Cyclacillin."
Clinical Note
moderateCyclacillin + Mycophenolic acid
"The serum concentration of the active metabolites of Mycophenolic acid can be reduced when Mycophenolic acid is used in combination with Cyclacillin resulting in a loss in efficacy."
Clinical Note
moderateCyclacillin + Plicamycin
"The serum concentration of Plicamycin can be decreased when it is combined with Cyclacillin."
Clinical Note
moderate0.5–1 hour in adults with normal renal function; prolonged to 10–15 hours in anuria.
CHLOROMYXIN is not a recognized drug. No data available.
Primarily renal (90%) as unchanged drug via glomerular filtration and tubular secretion; negligible biliary/fecal elimination (<5%).
Category C
Category C
Antibiotic
Antibiotic
Cyclacillin + Valrubicin
"The serum concentration of Valrubicin can be decreased when it is combined with Cyclacillin."